The Senolytic Protocol: Fisetin and Clearing Zombie Cells

The Senescent Cell Problem

Cellular senescence is a state of stable cell cycle arrest — cells that can no longer divide but refuse to die. In youth, senescent cells are cleared efficiently by the immune system. With age, clearance fails and senescent cells accumulate in tissues throughout the body.

The consequence is the Senescence-Associated Secretory Phenotype (SASP): senescent cells secrete a toxic cocktail of inflammatory cytokines (IL-6, IL-8, TNF-α), proteases, and growth factors that damage surrounding healthy cells, promote chronic inflammation, and impair tissue regeneration.

Senescent cell accumulation is implicated in virtually every age-related disease: osteoarthritis, cardiovascular disease, Alzheimer's, metabolic syndrome, and frailty. The exciting insight from the Kirkland and van Deursen labs at Mayo Clinic is that selectively clearing these cells in mice dramatically extends healthspan and lifespan — even when clearance begins in middle age.

Fisetin: A Potent Natural Senolytic

Fisetin is a flavonoid found in strawberries, apples, and onions at trace amounts, but used therapeutically at gram-level doses. Its senolytic activity was identified in a 2018 screen of 10 flavonoids by the Mayo Clinic group.

Mechanism: Fisetin kills senescent cells via multiple pathways:

• Inhibits the BCL-2/BCL-xL pro-survival proteins that keep senescent cells alive
• Activates Nrf2 pathway, reducing ROS that sustains senescent state
• Activates SIRT1/mTOR pathways promoting senescent cell autophagy
• Reduces SASP factor secretion in surviving senescent cells

Mouse data: The landmark 2018 EBioMedicine paper showed fisetin (100mg/kg daily for 5 days/month) reduced senescent cell markers by 25–50% in aged mouse tissues, improved physical function, and extended median lifespan by approximately 10% in aged mice.

The Pulsed Dosing Rationale

Senolytics require pulsed high-dose administration — not chronic daily supplementation. This is counterintuitive but mechanistically sound.

Senescent cells activate survival pathways (BCL-2, PI3K) to resist apoptosis — these are the same pathways fisetin inhibits. The cells are in a "primed" state, ready to die if survival signalling is sufficiently disrupted. A brief, high-dose pulse overwhelms their defences. Chronic low-dose supplementation maintains partial inhibition without triggering apoptosis — and may select for more resistant senescent cells over time.

Clinical translation protocol:

• Dose: 20mg/kg body weight (1,400mg for 70kg individual)
• Duration: 2 consecutive days per month
• Cycle: Monthly, assess every 3 months
• Form: Liposomal fisetin preferred for absorption; take with fat

Combining with Other Senolytics

The most-studied human senolytic combination is dasatinib + quercetin (D+Q) — a tyrosine kinase inhibitor (prescription) plus quercetin. This combination targets adipose tissue senescence particularly effectively.

For non-prescription protocols, fisetin as monotherapy has the strongest safety profile. Quercetin can be added (500–1000mg same days as fisetin) for potentially additive effects via complementary BCL-2/PI3K pathway inhibition.

Spermidine: Preventing New Senescence

Spermidine activates autophagy — clearing dysfunctional cellular components that drive cells toward senescence. While fisetin clears existing senescent cells, spermidine addresses upstream drivers.

The combination is rational: fisetin as monthly pulse (clearance), spermidine 1mg daily (prevention). Together they target the senescent cell burden from two directions.

Biomarkers for Tracking Senolytic Response

Circulating SASP markers can be measured:

• IL-6, TNF-α, CRP: general inflammatory load
• p16INK4a mRNA in peripheral blood (research use, not widely clinical)
• GDF-15: senescence-associated growth factor
• Functional measures: grip strength, gait speed, cognitive testing

Most practitioners track functional outcomes and inflammatory markers rather than cellular senescence directly.

Safety Considerations

Fisetin is generally well-tolerated at doses up to 20mg/kg. High single doses may cause transient GI discomfort — take with food during senolytic days. The theoretical oncological concern (that clearing BCL-2-dependent cells could affect healthy cell populations) has not been observed at these doses in preclinical or early human data.

⚕ For educational purposes only. High-dose fisetin protocols should be discussed with a physician, particularly in individuals with active medical conditions.